Bessemer Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Bessemer Group’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-50	Closed	-$1K	–	2112
2018 Q3	$1K	Hold	50	–	–	﹤0.01%	1799
2018 Q2	$0	Hold	50	–	–	﹤0.01%	1841
2018 Q1	$0	Hold	50	–	–	﹤0.01%	1838
2017 Q4	$0	Hold	50	–	–	﹤0.01%	1873
2017 Q3	$0	Hold	50	–	–	﹤0.01%	1934
2017 Q2	$1K	Hold	50	–	–	﹤0.01%	1801
2017 Q1	$1K	Hold	50	–	–	﹤0.01%	1721
2016 Q4	$0	Buy	+50	New	+$565	﹤0.01%	2120
2016 Q3	–	Sell	-5,400	Closed	-$70K	–	1903
2016 Q2	$70K	Hold	5,400	–	–	﹤0.01%	817
2016 Q1	$86K	Sell	5,400 -42,305	-89%	-$803K	﹤0.01%	806
2015 Q4	$1.37M	Buy	47,705 +300	+0.6%	+$8.31K	0.01%	495
2015 Q3	$1.35M	Sell	47,405 -12,115	-20%	-$446K	0.01%	498
2015 Q2	$2.14M	Hold	59,520	–	–	0.01%	399
2015 Q1	$1.73M	Buy	59,520 +11,320	+23%	+$299K	0.01%	434
2014 Q4	$1.02M	Buy	+48,200	New	+$953K	0.01%	472

Other funds holding INSY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bessemer Group's INSY Position: Q4 2018 in Review

Bessemer Group sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 50 shares — an estimated $1K sold.

Bessemer Group first reported a position in INSY in Q4 2014 and held it in 15 quarters. The position peaked at $2.14M in Q2 2015. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

Bessemer Group reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Bessemer Group sold 50 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $1K.
Bessemer Group first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 15 quarters.
Bessemer Group's Insys Therapeutics, Inc. position peaked at $2.14M in Q2 2015.
113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Bessemer Group's 13F filing for Q4 2018, filed 12 Feb 2019.